Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along ...

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

The vast majority of Medicare's top-selling brand-name oncology drugs in 2022 provided high added therapeutic benefit. Ten drugs were classified as low or no added therapeutic benefit compared ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...